Evonik Acquires a Surface Modification Technology Platform from Interface Biologics

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.
September 3, 2019

Evonik, a global leader in biomaterials for use in medical implant applications, today announced the acquisition of the Endexo® surface modification business of Interface Biologics, a privately-held material science company located in Toronto, Canada.

Evonik notes the acquisition is an important next step to further strengthen the capabilities of the growth engine Health & Care.

Endexo® is a proprietary additive technology that enhances the biocompatibility of medical devices that come into contact with blood, tissue or other biological fluids. The low molecular weight fluoro-oligomers used in Endexo® are incorporated during the device manufacturing process and migrate to within nanometres of the surface. By suppressing procoagulant protein conformation, decreasing platelet adhesion and inhibiting platelet activation, Endexo® reduces the risk of thrombotic events. It also suppresses bacteria adhesion and biofilm formation to reduce infection risk.

A number of medical device companies have licensed the use of the Endexo® technology in cardiovascular and other applications. Some of these products are already commercially available, while others are part of promising clinical trials.

“We are excited to onboard the Endexo® technology in our portfolio.” said Jean-Luc Herbeaux, SVP and General Manager of the Health Care business line of Evonik. “Endexo® expands our ability to serve as a development partner and solution provider to medical device companies worldwide. The team of Interface Biologics has done an exemplary job developing this innovative technology and bringing it to market. We look forward to applying our global business development capabilities and technical prowess to further expand the geographic and application footprint of Endexo®.”

“We have been working closely with Evonik on joint development opportunities over the last few years,” said Tom Reeves, President and CEO of Interface Biologics. “I am confident that the combination of the Endexo® technology platform and the technical, commercial and financial resources of Evonik will enable the rapid acceleration of the business across broad sectors of the medical device market.”

Additional terms of the agreement will not be disclosed.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.